EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-ASD-02(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Autism Spectrum Disorder is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
In accordance with the Supreme Court of India ruling and Ministry of Health & Family Welfare directives, all stem cell interventions for ASD in India are strictly restricted to approved clinical trials and institutional research protocols.
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory and trophic paracrine potential of clinical-grade mesenchymal stem cells to support tissue homeostasis, cellular repair, and inflammatory moderation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Children and adults with a formal clinical diagnosis of ASD (DSM-5 criteria, CARS/ADOS-2 scores).
Mandatory Pre-Procedure Diagnostics:
Pre-Screening Requirements: Baseline pediatric neurological assessment, EEG (evaluating subclinical seizure activity), metabolic screening, and complete blood count.
Strict Safety Exclusion Parameters:
Uncontrolled refractory epilepsy, active systemic infections, primary immunodeficiencies, or active malignancies.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Social Engagement: Incremental gains in eye contact, social responsiveness, and joint attention.
- Communication: Modest improvements in receptive language and non-verbal communicative intent.
- Sensory & Behavioral Regulation: Reductions in sensory overload, hyperactivity, and repetitive motor mannerisms.
Documented Procedural Risks & Limits:
- Mild post-procedure fever, fatigue, or localized soreness at the injection site (typically resolving within 24–48 hours).
- Risks associated with pediatric sedation or lumbar puncture (e.g., transient headache).
- No Guaranteed Benefit: Responses vary significantly; this intervention does not replace behavioral, speech, or occupational therapies.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Infrastructure
Research conducted within NABH- and JCI-accredited tertiary medical facilities.
Regulatory Compliance
Protocols overseen by an active, CDSCO/DHR-registered Institutional Ethics Committee (IEC).
Expertise
Supervised by licensed pediatric neurologists, developmental pediatricians, and certified regenerative medicine specialists.
Ethical Enrollment
Patients are accepted only if they satisfy strict inclusion criteria under active research protocols.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Travel Teleconsultation
Comprehensive video review with our pediatric medical team to evaluate suitability.
Visa & Travel Facilitation
Official Medical Visa (MED) and Attendant Visa (MED-X) invitation documentation approved by the Government of India.
Dedicated International Liaison
Personalized multilingual assistance for hospital navigation, scheduling, and local transit.
Post-Discharge Monitoring
Structured virtual follow-ups at 1, 3, 6, and 12 months, coordinating directly with your home behavioral therapists.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Airport Transfers
Accessible, private airport pick-up and drop-off to reduce transit stress for sensitive children.
Family-Centered Accommodations
Low-sensory private hospital suites with family amenities, or vetted partner apartments within 3 km of the hospital.
Personalized Support
Dietary customization (GFCF, allergen-free, sensory-adapted textures), high-speed connectivity, and 24/7 nursing availability.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 5-day structured in-hospital protocol.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Autism Spectrum Disorder
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Phase II Randomized, Placebo-Controlled Trial of Autologous Cord Blood in Children with ASD
Dawson, G., Sun, J. M., Baker, J., Carpenter, K., Compton, S., Deaver, M., Franz, L., Heilbron, N., Herold, B., Horrigan, J., Howard, J., Kosinski, A., Major, S., Murias, M., Page, K., Prasad, V. K., Sabatos-DeVito, M., Sanfilippo, F., Sikich, L., Simmons, R., Song, A. W., Vermeer, S., Waters-Pick, B., Troy, J., & Kurtzberg, J. (2020). A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. The Journal of Pediatrics, 222, 164–173.e5.
Randomized Double-Blind, Placebo-Controlled Trial of Cord Blood vs. Umbilical Cord Tissue MSCs
Sun, J. M., Dawson, G., Franz, L., Howard, J., McLaughlin, C., Kistler, B., Waters-Pick, B., Meadows, N., Troy, J., & Kurtzberg, J. (2020). Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Translational Medicine, 9(10), 1137–1146.
Controlled Clinical Trial on Bone Marrow Mononuclear Cells in Severe Autism
Sharma, A., Gokulchandran, N., Sane, H., Nagrajan, A., Aranha, A., Kulkarni, P., & Biju, H. (2013). Autologous bone marrow mononuclear cell transplantation in autism: an open label proof of concept study. Stem Cells International, 2013, 623875.
Systematic Review & Meta-Analysis of Stem Cell Interventions in ASD
Qu, J., Liu, Z., Li, L., Zou, Z., He, Z., Zhou, L., & Hu, X. (2022). Efficacy and safety of stem cell therapy in children with autism spectrum disorder: a systematic review and meta-analysis. Stem Cell Research & Therapy, 13(1), 295.
Statutory Notice & Mandatory Regulatory Disclosure:
Under the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), as well as current National Medical Commission (NMC) directives, stem cell therapy is not approved as a standard clinical care treatment for Autism Spectrum Disorder. It is available solely within the framework of approved clinical research and trials under registered Institutional Ethics Committee supervision. It must not be marketed as a routine commercial procedure or cure. Continuous behavioral interventions (ABA, speech, occupational therapy) remain the standard of care.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.